Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
CYTOKINETICS INC (CYTK) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Other Events  Interactive Data
10/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Cytokinetics, Incorporated Executive Severance Plan and Summary Plan Description",
"Cytokinetics, Incorporated Executive Severance Plan and Summary Plan Description"
08/03/2023 8-K Quarterly results
Docs: "CYTOKINETICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Completed Enrollment in SEQUOIA-HCM, Pivotal Phase 3 Trial of Aficamten in Obstructive HCM; On Track for Topline Results by the End of the Year Initiated Enrollment in MAPLE-HCM, a Phase 3 Clinical Trial Comparing Aficamten and Metoprolol in Obstructive HCM ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM, Expected to Start in September 2023 Company Reduces Projected Spending by Approximately 15% and Revises 2023 Financial Spending Guidance SOUTH SAN FRANCISCO, Calif., Aug. 3, 2023 -"
05/22/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CYTOKINETICS PRESENTS NEW DATA IN PATIENTS WITH NON-OBSTRUCTIVE HCM FROM COHORT 4 OF REDWOOD-HCM IN LATE-BREAKING CLINICAL TRIAL SESSION AT THE EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2023 CONGRESS Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To Begin in 2H 2023 SOUTH SAN FRANCISCO, Calif., May 20, 2023"
05/11/2023 8-K Other Events  Interactive Data
05/11/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/04/2023 8-K Quarterly results
03/31/2023 8-K Quarterly results
03/06/2023 8-K Other Events  Interactive Data
03/01/2023 8-K Quarterly results
Docs: "CYTOKINETICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the American College of Cardiology Scientific Sessions; Results Expected from SEQUOIA-HCM in Q4 2023 Second Interim Analysis of COURAGE-ALS Expected to Occur in Q2 2023 Company Provides 2023 Financial Guidance; More than 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif., Mar. 1, 2023 -"
02/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Compensation Information for the Company’s Named Executive Officers Robert I. Blum, President & Chief Executive Officer: · 2023 base salary $790,000; · 2022 bonus award $395,705; and · 2023 target bonus is 75% of base salary. Ching W. Jaw, Senior Vice President, Finance and Chief Financial Officer: · 2023 base salary $525,971; · 2022 bonus award $193,145; and · 2023 target bonus is 45% of base salary. Fady I. Malik, Executive Vice President, Research and Development: · 2023 base salary $586,023; · 2022 bonus award $207,829; and · 2023 target bonus is 45% of base salary. Andrew Callos, Executive Vice President, Chief Commercial Officer: · 2023 base salary $523,640; · 2022 bonus award $189,511; and · 2023 tar..."
01/09/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "ACTIVATE INHIBIT INHIBIT ACTIVATE ACTIVATE ACTIVATE"
12/13/2022 8-K Other Events  Interactive Data
12/08/2022 8-K Quarterly results
12/08/2022 8-K Quarterly results
12/07/2022 8-K Quarterly results
11/07/2022 8-K Other Events  Interactive Data
11/03/2022 8-K Quarterly results
10/11/2022 8-K Other Events  Interactive Data
10/03/2022 8-K Quarterly results
09/30/2022 8-K Quarterly results
08/04/2022 8-K Other Events  Interactive Data
08/04/2022 8-K Quarterly results
Docs: "CYTOKINETICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023 Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022 SOUTH SAN FRANCISCO, Calif., Aug. 4, 2022 -"
07/06/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy